However, Ozempic is represented to be one of the GLP-1 receptor agonist medicines that was primarily developed to treat type 2 diabetes but has been discussed lately as regards overweight reduction medicines
J Pharm Invest 118 Griffith DA, Edmonds DJ, Fortin J-P, Kalgutkar AS, Kuzmiski JB, Loria PM, Saxena AR, Bagley SW, Buckeridge C, Curto JM, Derksen DR, Dias JM, Griffor MC, Han S, Jackson VM, Landis MS, Lettiere D, Limberakis C, Liu Y, Mathiowetz AM, Patel JC, Piotrowski DW, Price DA, Ruggeri RB, Tess DA (2022) A small-molecule oral agonist of the human glucagon-like peptide-1 receptor
Long-term effects beyond six months are not well established
It also promotes satiety, or a feeling of fullness
Questions and Answers There are no questions yet